Legal Firm Announces Class Action Suit for Biohaven Investors Facing Significant Losses

Legal firm Bronstein, Gewirtz & Grossman LLC has announced that investors affected by significant losses in Biohaven Ltd. (NYSE: BHVN) have the opportunity to lead a class action lawsuit. The lawsuit targets alleged violations of federal securities laws committed by Biohaven and some of its executives during the period from March 24, 2023, to May 14, 2025. Investors who purchased Biohaven securities during this timeframe are encouraged to join the case by visiting the firm's website at bgandg.com/BHVN. The complaint claims that throughout the class period, Biohaven's management made misleading statements regarding the company's drug development prospects, including overstating the potential of troriluzole for SCA and BHV-7000 for bipolar disorder. These false statements, once revealed, are believed to have adversely impacted the company's financial health. Individuals who suffered losses due to these alleged misconduct have until September 12, 2025, to seek appointment as lead plaintiff. The firm offers representation on a contingency fee basis, meaning clients pay only if the case is successful. For more information or to review the complaint, interested parties can contact Bron...